Clinical implications of human papillomavirus genotype in cervical adeno-adenosquamous carcinoma

Published:October 01, 2012DOI:



      Our aims were to evaluate the genotype distribution of human papillomavirus (HPV) and the correlation between HPV parameters and clinicopathological/treatment variables with prognosis in cervical adeno-adenosquamous carcinoma (AD/ASC).

      Patients and methods

      Consecutive patients who received primary treatment for cervical AD/ASC International Federation of Gynecology and Obstetrics (FIGO) stages I–IV between 1993 and 2008 were retrospectively reviewed. Prognostic models were constructed and followed by internal validation with bootstrap resampling.


      A total of 456 AD/ASC patients were eligible for HPV genotyping, while 452 were eligible for survival analysis. HPV18 was detected in 51.5% and HPV16 in 36.2% of the samples. Age >50 years old, FIGO stages III–IV and HPV16-negativity were significantly related to cancer relapse, and age >50, FIGO stages III–IV, HPV16-negativity and HPV58-positivity were significant predictors for cancer-specific survival (CSS) by multivariate analyses. HPV16-positivity was also significantly associated with good prognosis in those receiving primary radiotherapy or concurrent chemoradiation (RT/CCRT) (CSS: hazard ratio 0.41, 95% confidence interval 0.21–0.78). Patients with FIGO stages I–II and HPV16-negative AD/ASC treated with primary RH-PLND had significantly better CSS (p< 0.0001) than those treated with RT/CCRT.


      Age >50 years old, FIGO stages III–IV and HPV16-negativity were significant poor prognostic factors in cervical AD/ASC. Patients with HPV16-negative tumour might better be treated with primary surgery (e.g. radical hysterectomy for stages I–II and pelvic exenteration for stage IVA). Those with unresectable HPV16-negative tumour (stage IIIB) should undergo CCRT in combination with novel drugs. The inferences of a single-institutional retrospective study require prospective studies to confirm.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. GLOBOCAN 2008. <> [accessed May 30, 2012].

        • Wang S.S.
        • Sherman M.E.
        • Hildesheim A.
        • et al.
        Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976–2000.
        Cancer. 2004; 100: 1035-1044
        • Chen Y.Y.
        • You S.L.
        • Chen C.A.
        • et al.
        Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences.
        Br J Cancer. 2009; 101: 174-177
        • Bray F.
        • Carstensen B.
        • Moller H.
        • et al.
        Incidence trends of adenocarcinoma of the cervix in 13 European countries.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 2191-2199
        • Castellsague X.
        • Diaz M.
        • de Sanjose S.
        • et al.
        Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
        J Natl Cancer Inst. 2006; 98: 303-315
        • International Collaboration of Epidemiological Studies of Cervical Cancer
        Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8097 women with squamous cell carcinoma and 1374 women with adenocarcinoma from 12 epidemiological studies.
        Int J Cancer. 2007; 120: 885-891
        • Chao A.
        • Wang T.H.
        • Lee Y.S.
        • et al.
        Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression.
        Int J Cancer. 2006; 119: 91-98
        • Waggoner S.E.
        Cervical cancer.
        Lancet. 2003; 361: 2217-2225
        • Rose P.G.
        Are the differences in treatment outcome for adenocarcinoma of the cervix different endough to change the treatment paradigm?.
        Gynecol Oncol. 2012; 125: 285-286
        • Hong J.H.
        • Tsai C.S.
        • Wang C.C.
        • et al.
        Comparison of clinical behaviors and responses to radiation between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas of the cervix.
        Chang Gung Med J. 2000; 23: 396-404
        • An H.J.
        • Kim K.R.
        • Kim I.S.
        • et al.
        Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study.
        Mod Pathol. 2005; 18: 528-534
        • Clifford G.
        • Franceschi S.
        Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix.
        Int J Cancer. 2008; 122: 1684-1685
        • Lai C.H.
        • Chang C.J.
        • Huang H.J.
        • et al.
        Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery.
        J Clin Oncol. 2007; 25: 3628-3634
        • Wang C.C.
        • Lai C.H.
        • Huang H.J.
        • et al.
        Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy.
        Int J Radiat Oncol Biol Phys. 2010; 78: 1111-1120
        • Kang W.D.
        • Kim C.H.
        • Cho M.K.
        • et al.
        HPV-18 is a poor prognostic factor, unlike the HPV viral load, in patients with stage IB-IIA cervical cancer undergoing radical hysterectomy.
        Gynecol Oncol. 2011; 121: 546-550
        • Kim S.Y.
        • Park S.P.
        • Nam B.H.
        • et al.
        Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy.
        J Clin Oncol. 2009; 27: 5088-5093
        • Lai C.H.
        • Huang H.J.
        • Hsueh S.
        • et al.
        Human papillomavirus genotype in cervical cancer: a population-based study.
        Int J Cancer. 2007; 120: 1999-2006
        • Chao A.
        • Jao M.S.
        • Huang C.C.
        • et al.
        Human papillomavirus genotype in cervical intraepithelial neoplasia grade 2 and 3 of Taiwanese women.
        Int J Cancer. 2011; 128: 653-659
        • Lai C.H.
        • Tang S.G.
        • Chang T.C.
        • et al.
        Implications of a failed prospective trial of adjuvant therapy after radical hysterectomy for stage Ib-IIa cervical carcinoma with pelvic node metastases.
        Chang Gung Med J. 1998; 21: 291-299
        • Hong J.H.
        • Tsai C.S.
        • Lai C.H.
        • et al.
        Postoperative low-pelvic irradiation for stage I–IIA cervical cancer patients with risk factors other than pelvic lymph node metastasis.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1284-1290
        • Chao A.
        • Ho K.C.
        • Wang C.C.
        • et al.
        Positron emission tomography in cervical cancer patients with limited distant lymph node metastases.
        Gynecol Oncol. 2008; 110: 171-178
        • Steyerberg E.W.
        • Harrell Jr., F.E.
        • Borsboom G.J.
        Internal validation of predictive models: efficiency of some procedures for logistic regression analysis.
        J Clin Epidemiol. 2001; 54: 774-781
        • Chan P.K.
        • Ho W.C.
        • Yu M.Y.
        • et al.
        Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades.
        Int J Cancer. 2009; 125: 1671-1677
        • Paavonen J.
        • Naud P.
        • Salmeron J.
        • et al.
        Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
        Lancet. 2009; 374: 301-314
        • The FUTURE II Study Group
        Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
        N Engl J Med. 2007; 356: 1915-1927
        • Baalbergen A.
        • Ewing-Graham P.C.
        • Hop W.C.
        • et al.
        Prognostic factors in adenocarcinoma of the uterine cervix.
        Gynecol Oncol. 2004; 92: 262-267
        • Kasamatsu T.
        • Onda T.
        • Sawada M.
        • et al.
        Radical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervix.
        Br J Cancer. 2009; 100: 1400-1405
        • Chou H.H.
        • Chang H.P.
        • Lai C.H.
        • et al.
        18F-FDG PET in stage IB/IIB in cervical adeno-adenosquamous carcinoma.
        Eur J Nucl Med Mol Imaging. 2010; 37: 728-735
        • Huang Y.T.
        • Hong J.H.
        • Tsai C.S.
        • et al.
        Long term outcome and prognostic factors for adenocarcinomas/adenosquamous carcinomas of cervix after definitive radiotherapy.
        Int J Radiat Oncol Biol Phys. 2011; 80: 429-436
        • Ragin C.C.
        • Taioli E.
        Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis.
        Int J Cancer. 2007; 121: 1813-1820
        • Kreimer A.R.
        • Clifford G.M.
        • Boyle P.
        • et al.
        Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.
        Cancer Epidemiol Biomarkers Prev. 2005; 14: 467-475
        • Klussmann J.P.
        • Mooren J.J.
        • Lehnen M.
        • et al.
        Genetic signatures of HPV-related and unrelated oropharygeal carcinoma and their prognostic implications.
        Clin Cancer Res. 2009; 15: 1779-1786